Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients

European Respiratory Journal

Volumn 27, Issue 6, 2006, Pages 1190-1195

  Muller Quernheim J ^a   Gaede, K I ^a,b   Fireman, E ^c   Zissel, G ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b RESEARCH CENTER BORSTEL   (Germany)

^c TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Chronic beryllium disease; Diagnosis; Lymphocyte proliferation test; Sarcoidosis

Indexed keywords

BERYLLIUM;

ADULT; AGED; ARTICLE; BERYLLIOSIS; CHRONIC DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GRANULOMATOSIS; HEALTH HAZARD; HUMAN; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL LUNG DISEASE; PRIORITY JOURNAL; WORKPLACE; CLINICAL TRIAL; COMORBIDITY; GERMANY; ISRAEL; MIDDLE AGED; MULTICENTER STUDY; RISK FACTOR; SARCOIDOSIS; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; BERYLLIOSIS; COMORBIDITY; DIAGNOSIS, DIFFERENTIAL; FEMALE; GERMANY; HUMANS; ISRAEL; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; RISK FACTORS; SARCOIDOSIS;

EID: 33750697248     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00112205     Document Type: Article

References (39)

1. Newman LS, Kreiss K, King TE Jr, Seay S, Campbell PA. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history. Am Rev Respir Dis 1989; 139: 1479-1486.
2. Maier LA. Genetic and exposure risks for chronic beryllium disease. Clin Chest Med 2002; 23: 827-839.
3. Rossman MD, Kreider ME. Is chronic beryllium disease sarcoidosis of known etiology? Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 104-109.
4. Willis HH, Florig HK. Potential exposures and risks from beryllium-containing products. Risk Anal 2002; 22: 1019-1033.
5. Infante PF, Newman LS. Beryllium exposure and chronic beryllium disease. Lancet 2004; 363: 415-416.
6. Newman LS. Beryllium disease and sarcoidosis: clinical and laboratory links. Sarcoidosis 1995; 12: 7-19.
7. Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336: 1224-1234.
8. Kent DC, Houk VN, Elliott RC, Sokolowski JW Jr, Baker JH, Sorensen K. The definitive evaluation of sarcoidosis. Am Rev Respir Dis 1970; 101: 721-727.
9. Fireman E, Haimsky E, Noiderfer M, Priel I, Lerman Y. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease. Sarcoidosis Vasc Diffuse Lung Dis 2003; 20: 144-148.
10. Newman LS, Kreiss K. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am Rev Respir Dis 1992; 145: 1212-1214.
11. Lang L. Beryllium: a chronic problem. Environ Health Perspect 1994; 102: 526-531.
12. Mroz MM, Kreiss K, Lezotte DC, Campbell PA, Newman LS. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease. J Allergy Clin Immunol 1991; 88: 54-60.
13. Stokes RF, Rossman MD. Blood cell proliferation response to beryllium: analysis by receiver-operating characteristics. J Occup Med 1991; 33: 23-28.
14. Stange AW, Furman FJ, Hilmas DE. The beryllium lymphocyte proliferation test: relevant issues in beryllium health surveillance. Am J Ind Med 2004; 46: 453-462.
15. Wemme H, Pfeifer S, Heck R, Müller-Quernheim J. Measurement of lymphocyte proliferation: critical analysis of radioactive and photometric methods. Immunobiology 1992; 185: 78-89.
16. Frome EL, Smith MH, Littlefield LG, Neubert RL, Colyer SP. Statistical methods for the blood beryllium lymphocyte proliferation test. Environ Health Perspect 1996; 104: Suppl. 5, 957-968.
17. Judd NL, Griffith WC, Takaro T, Faustman EM. A model for optimization of biomarker testing frequency to minimize disease and cost: example of beryllium sensitization testing. Risk Anal 2003; 23: 1211-1220.
18. Newman LS, Lloyd J, Daniloff E. The natural history of beryllium sensitization and chronic beryllium disease. Environ Health Perspect 1996; 104S: 937-943.
19. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. Human leukocyte antigen class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am J Respir Crit Care Med 2002; 165: 788-794.
20. Newman LS, Mroz MM, Balkissoon R, Maier LA. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am J Respir Crit Care Med 2005; 171: 54-60.
21. Bartell SM, Ponce RA, Takaro TK, Zerbe RO, Omenn GS, Faustman EM. Risk estimation and value-of-information analysis for three proposed genetic screening programs for chronic beryllium disease prevention. Risk Anal 2000; 20: 87-99.
22. Sood A, Beckett WS, Cullen MR. Variable response to long-term corticosteroid therapy in chronic beryllium disease. Chest 2004; 126: 2000-2007.
23. Sprince NL, Kanarek DJ, Weber AL, Chamberlin RI, Kazemi H. Reversible respiratory disease in beryllium workers. Am Rev Respir Dis 1978; 117: 1011-1017.
24. Rossman MD. Chronic beryllium disease: diagnosis and management. Environ Health Perspect 1996; 104S: 945-947.
25. Verma DK, Ritchie AC, Shaw ML. Measurement of beryllium in lung tissue of a chronic beryllium disease case and cases with sarcoidosis. Occup Med (Lond) 2003; 53: 223-227.
26. Karkinen-Jaaskelainen M, Maatta K, Pasila M, Saxen L. Pulmonary berylliosis: report on a fataf case. Br J Dis Chest 1982; 76: 290-297.
27. Richeldi L, Sorrentino R, Saltini C. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 1993; 262: 242-244.
28. Weston A, Ensey J, Kreiss K, Keshava C, McCanlies E. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease. Am J Ind Med 2002; 41: 457-465.
29. Gaede KI, Amicosante M, Schurmann M, Fireman E, Saltini C, Muller-Quernheim J. Function associated transforming growth factor-beta gene polymorphism in chronic beryllium disease. J Mol Med 2005; 83: 397-405.
30. Amicosante M, Berretta F, Franchi A, et al. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells. Eur Respir J 2002; 20: 1174-1178.
31. Amicosante M, Berretta F, Rossman M, et al. Identification of HLA-DRPhebeta47 as the susceptibility marker of hypersensitivity to beryllium in individuals lacking the berylliosis-associated supratypic marker HLA-DPGlubeta69. Respir Res 2005; 6: 94.
32. Rossman MD, Thompson B, Frederick M, et al. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003; 73: 720-735.
33. Tinkle SS, Antonini JM, Rich BA, et al. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ Health Perspect 2003; 111: 1202-1208.
34. Taylor TP, Ding M, Ehler DS, Foreman TM, Kaszuba JP, Sauer NN. Beryllium in the environment: a review. J Environ Sci Health A Tox Hazard Subst Environ Eng 2003; 38: 439-469.
35. Rossman MD, Kern JA, Elias JA, et al. Proliferative response of bronchoalveolar lymphocytes to beryllium: a test for chronic beryllium disease. Ann Intern Med 1988; 108: 687-693.
36. Pott GB, Palmer BE, Sullivan AK, et al. Frequency of beryllium-specific, TH1-type cytokine-expressing CD4+ T cells in patients with beryllium-induced disease. J Allergy Clin Immunol 2005; 115: 1036-1042.
37. Middleton DC, Lewin MD, Kowalski PJ, Cox SS, Kleinbaum D. The BeLPT: algorithms and implications. Am J Ind Med 2006; 49: 36-44.
38. Deubner DC, Lowney YW, Paustenbach DJ, Warmerdam J. Contribution of incidental exposure pathways to total beryllium exposures. Appl Occup Environ Hyg 2001; 16:568-578.
39. Paustenbach DJ, Madl AK, Greene JF. Identifying an appropriate occupational exposure limit (OEL) for beryllium: data gaps and current research initiatives. Appl Occup Environ Hyg 2001; 16: 527-538.